ArticleTranslational oncology2026
Integrative multi-omics and network analysis identify potential targets of Chaihu Shugan Xiaozheng Formula in breast cancer.
Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic potential and mechanisms of rehabilitation interventions in preventing cancer metastasis.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer (BC) is linked to emotional stress and neuroendocrine-immune dysregulation. Chaihu Shugan Xiaozheng Formula (CSXF) shows clinical efficacy in BC with depressive symptoms, yet its mechanisms remain unclear. This study aims to investigate the therapeutic effects of CSXF in modulating neuroendocrine-immune networks and tumor-related pathways in BC.
methodsThe bioactive compounds of CSXF were screened using the TCMSP database. Target genes that intersected with differentially expressed genes associated with BC from the TCGA-BRCA dataset were analyzed. Prognostic signatures were constructed through Cox and LASSO regression models. Multi-omics profiling included immune infiltration, pathway enrichment, molecular docking, and RT-qPCR validation in BC tissue samples.
resultsFive core targets formed a prognostic model with high predictive accuracy. High-risk patients exhibited elevated mortality independent of age/NM stage. Oxidative phosphorylation activation and myeloid-derived suppressor cell infiltration correlated with CD14 overexpression in high-risk groups. RT-qPCR confirmed tumor-specific downregulation of CD14, PPARG, and CHRM1 in BC tissues.
conclusionsCSXF treats BC via multi-target modulation of neuroendocrine-immune and tumor pathways, providing prognostic biomarkers and mechanistic insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.